Biogen Pays $124 Million to Develop Gene-Based Therapies

Biogen

Biogen Pays $124 Million to Develop Gene-Based Therapies

On Thursday, Biogen Inc. will enter into the area of eye-disease treatment by paying Applied Genetic Technologies Corp. (AGTC) about $124 million for licensing its products, and commercialization rights to a few of its gene-based therapies.

Where, the amount ($124 million) incorporates a $30 million equity investment worth of $20.63 per share. Biogen also has the choice to licensing discovery programs for three additional symptoms. The company plans to develop gene-based therapies for a range of eye diseases.

AGTC is qualified to get point of milestone payments summing up to $1 billion, incorporating up to $472.5 million for the two lead projects, and a large portion of the rest coming from payments for the potential discovery programs.

The two lead projects include in the agreement are a pre-clinical treatment for X-Linked Retinitis Pigmentosa, and a clinical candidate for a disease called X-linked Retinoschisis. These are diseases of the retina, which can cause visual impairment in men.

AGTC Chief Executive Sue Washer said that the combined effort would bolster the development of new treatments, which may consider transformative medications for these rare inherited eye diseases.

Alachua, Fla-based AGTC specializes in developing gene-therapy medicines for eye diseases. The therapy is still in its nascent stages. The most common type of the treatment takes healthy DNA, bundles it inside of a vector; a biological delivery mechanism; and after that delivers the vector into the body to supplant infected genes with the healthy DNA.

Massachusetts-based Biogen has been looking for new products to increase sales growth, after experiencing a successful 2013 launch of its various multiple-sclerosis therapies – Tecfidera. In its most recent quarter, slowing growth of Tecfidera led to lower than expected profit, and revenue growth.

Market Review: Shares of Biogen have increased sales of about 19 per cent, this year through Wednesday’s close. The deal is expected to shut down in the third quarter of the year. In recent trading, the shares of AGTC climbed to 17 per cent, while the shares of Biogen were relatively flat.

Carrie Ann
Carrie Ann is Editor-in-Chief at Industry Leaders Magazine, based in Las Vegas. Carrie covers technology, trends, marketing, brands, productivity, and leadership. When she isn’t writing she prefers reading. She loves reading books and articles on business, economics, corporate law, luxury products, artificial intelligence, and latest technology. She’s keen on political discussions and shares an undying passion for gadgets. Follow Carrie Ann on Twitter, Facebook

Recent Posts

The chip shortage is a ‘short-term’ problems, says Elon Musk

The chip shortage is a ‘short-term’ problems, says Elon Musk

The CEO’s outlook is far more optimistic than other automotive industry leaders who believe it may last up to 2023-24.
12 hours ago
Supply chain crisis bad news for automotive industry leaders

Supply chain crisis bad news for automotive industry leaders

The world’s biggest car companies are on track to lose production of 7.7 million vehicles in 2021. The forecast advices automakers on supply chain and other issues.
3 days ago
Scammers dupe Apple fans with free bitcoin lure

Scammers dupe Apple fans with free bitcoin lure

Savvy scammers used a fake event stream, a fake Apple website, and the promise of free bitcoin to lure fans into opening up their wallets.
4 days ago
Japan’s MUFG offloads Union Bank to U.S. Bancorp for $7.3 billion

Japan’s MUFG offloads Union Bank to U.S. Bancorp for $7.3 billion

The total amount of cash to be received as part of MUFG Union Bank’s sale to Bancorp is $7.3 billion (800 billion yen).
5 days ago
Evergrande: A black swan event that could spook markets

Evergrande: A black swan event that could spook markets

EverGrande is now known as the “world’s most indebted property developer” and serves as a symbol of corporate excess.
6 days ago
Moderna vaccine more effective than Pfizer, study says

Moderna vaccine more effective than Pfizer, study says

Moderna’s Covid-19 vaccine does a slightly better job of preventing coronavirus-related hospitalizations and emergency department visits.
1 week ago